**SLAMTB**

**GENOMIC AND EPIDEMIOLOGY**

**GENOMICA Y EPIDEMIOLOGIA**

“Tracing the evolution of *Mycobacterium tuberculosis* outbreak strains in time and space” Vegard Eldholm, Norwegian Institute of Public Health, Oslo; Norwich.

“Evolution and epidemiology of MDR-TB”. Sebastian Gagneux, University of Basel; Suiza.

“High throughput genomic analysis to rewind the clock on the evolution of drug resistant tuberculosis”. Ashlee Earl, BROAD, MIT, Boston; USA

“Relationship between genetic background, isoniazid resistance mutation, and clustering of drug resistant *Mycobacterium tuberculosis* in Argentina”. Viviana Rittacco, ANLIS MALBRAN, Buenos Aires; Argentina

**IMMUNOLOGY**

**INMUNOLOGIA**

“The immune-endocrine component of tuberculosis pathophysiology”. Oscar Bottasso, Facultad de Ciencias Médicas, UNR, Rosario; Argentina.

“Study of the immune mechanisms that control tuberculosis infection in the human host”. Verónica García, FCEN UBA, Buenos Aires; Argentina.

“How M. tuberculosis manipulates the immune response? Modulation of human macrophage programming in Tuberculosis”. Luciana Balboa, IMEX-CONICET, Buenos Aires; Argentina.

“The non-successful application of BCG vaccination fuels the virulence of Mycobacterium tuberculosis”. Rogelio Hernandez-Pando, INST. Salvador Zubirán, Cdad de México; Mexico.

“Papel de Tim-3 en la inmunidad contra la infección por Mycobacterium tuberculosis”. Isabel Sada Ovalle, National Institute of Respiratory Diseases Ismael Cosio Villegas , Cdad de México; Mexico.

**CELLULAR BIOLOGY**

**BIOLOGIA CELULAR**

“Beyond macrophages: lymphatic endothelial cells in tuberculosis”. Maximiliano Gutiérrez, The Francis Crick Institute, London; UK.

“*Mycobacterium* and autophagy: many unsolved questions”. Marisa Colombo, IHEM- UNCuyo, Mendoza; Argentina.

“Functional characterization of thiol-dependent peroxidases from *Mycobacterium tuberculosis*”. Madia Trujillo, Universidad de la República; Uruguay.

**CLINIC AND DTS**

**CLINICA Y DTS**

“Visión clínica de la TB-DR”. Domingo Palmero, Hospital de Enfermedades Infecciosas Francisco Javier Muñiz, Ciudad de Buenos Aires; Argentina.

“Fluophages for rapid assessment of *M. tuberculosis* viability”. Mariana Piuri, FCEN UBA, Buenos Aires; Argentina.

“Clinical cases of tuberculosis boarded by mycobacteria whole genome sequencing”. Carlos Robello, IP Mont, Montevideo; Uruguay.

“TBC. Ampliando la controversia entre tratamiento supervisado vs autoadministrado”. F. Rubinstein, Instituto de Efectividad Clínica, Buenos Aires; Argentina.

**MYCOBACTERIA IN VETERINARY**

**MYCOBACTERIAS DE IMPORTANCIA VETERINARIA**

“Using the cattle model of tuberculosis to discover host markers of protection and disease to facilitate the development of vaccines and immune-diagnostic tests”. Martin Vordermeier, Animal and Plant Health Agency (APHA), United Kingdom.

“First line Molecular diagnosis of bovine tuberculosis in France and its articulation with the new reinforced national control program”. Laura Boschiroli, ANSES, París; France.

“Avances en epidemiología de la infección por Mycobacterium avium subsp. Paratuberculosis”. Miguel Salgado, Universidad Austral de Chile; Chile.

“Cell Wall lipopeptides of Mycobacterium avium: New insights from genomics analysis”. Franc Biet, INRA Centre Val de Loire; France.

**DRUGS ACTION MECHANISMS AND DRUG DEVELOPMENTS**

**MECANISMOS DE ACCION DE DROGAS Y DESARROLLOS DE DROGAS**

“Esencial Acyl-CoA carboxylases as targets for the identification on new antimycobacterial hits”. Hugo Gramajo, IBR, UNR CONICET, Rosario; Argentina.

“Efflux and the unsighted world of sub-inhibitory antibiotic concentrations” Pedro Almeida da Silva, Univ Federal de Rio Grande; Brazil.

“TB Drug Discovery 2016: an update from the trenches”. Clifton E. Barry3°, NIAID-NIH, Bethesda, MD; USA.

**MYCOBACTERIAL BIOLOGY AND PHYSIOLOGY**

**PATOGENICIDAD Y VIRULENCIA**

“Combinatorial genetic strategies to dissect TB pathgenesis”. Christopher  Sassetti, University of Massachusetts Medical School, Worcester; USA.

“Transcriptómica global de M. tuberculosis durante su adaptación a hipoxia en el modelo “in vitro” de ácidos grasos”. Patricia del Portillo, CORPOGEN; Bogotá; Colombia.

“Mycobacterial bacilli - differences among twins”. Eric Rubin, Division of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; USA.

“Energy metabolism in tuberculosis”. Adrie Steyn, Nelson R. Mandela School of Medicine,

Durban; South Africa.

“TLR4 and DCSIGN receptors recognized by Mycobacterium scrofulaceum promoted semiactivated phenotype in Bloom marrow dendritics cells”. Yolanda López Vidal, UNAM, Cdad de México; Mexico.

**VACCINE CONFERENCES**

**CONFERENCIA EN VACUNAS**

“A strategy for new vaccines against TB”. Willem Hanekom, Gates Foundation; Seattle, USA.

“Investigación y desarrollo de MTBVAC, una nueva vacuna atenuada contra la tuberculosis en ensayos clínicos”. Carlos Martín, Universidad de Zaragoza; Zaragoza; Spain.